| Nov 19 |
Eyenovia downgraded to Neutral from Buy at H.C. Wainwright
|
| Nov 18 |
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study
|
| Nov 18 |
Eyenovia stock plummets following Phase III myopia trial failure
|
| Nov 15 |
Sector Update: Health Care Stocks Slide Late Afternoon
|
| Nov 15 |
Crude Oil Dips Over 2%; Bloom Energy Shares Spike Higher
|
| Nov 15 |
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
|
| Nov 15 |
Eyenovia plunges as late-stage trial for myopia treatment fails
|
| Nov 15 |
Eyenovia Third Quarter 2024 Earnings: Misses Expectations
|
| Nov 15 |
Eyenovia Provides Update on Phase 3 CHAPERONE Study
|
| Nov 13 |
Eyenovia Inc (EYEN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
|
